Table 3.
Model 1 (HbA1c, SBP, DBP and LDL-C) vs. model 2 (model 1 + SUA) | ||||
---|---|---|---|---|
Models | AUC (95% CI) | ΔAUC | IDI (±SE) | Relative IDI* (%) |
CAC progression (n=199) | ||||
Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.67 (0.62–0.73) | |||
Model 1 + SUA (model 1: HbA1c, SBP, DBP and LDL-C) | 0.72 (0.68–0.77) | |||
SUA + Model 1 vs Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.05 (p=0.005) | 0.05±0.01 (p<0.0001) | 12.2% (p<0.0001) | |
Incident albuminuria (n=27) | ||||
Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.67 (0.55–0.80) | |||
Model 1 + SUA (model 1: HbA1c, SBP, DBP and LDL-C) | 0.73 (0.61–0.84) | |||
SUA + Model 1 vs Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.06 (p=0.20) | 0.04±0.02 (p=0.02) | 35.1% (p=0.02) | |
Rapid GFR decline (n=50) | ||||
Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.69 (0.60–0.77) | |||
Model 1 + SUA (model 1: HbA1c, SBP, DBP and LDL-C) | 0.70 (0.62–0.79) | |||
SUA + Model 1 vs Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.02 (p=0.27) | 0.01±0.01 (p=0.11) | 6.5% (p=0.11) | |
Incident diabetic retinopathy (n=71) | ||||
Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.65 (0.58–0.72) | |||
Model 1 + SUA (model 1: HbA1c, SBP, DBP and LDL-C) | 0.68 (0.61–0.75) | |||
SUA + Model 1 vs Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.03 (p=0.19) | 0.02±0.01 (p=0.01) | 14% (p=0.01) | |
Incident peripheral diabetic retinopathy (n=35) | ||||
Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.73 (0.64–0.82) | |||
Model 1 + SUA (model 1: HbA1c, SBP, DBP and LDL-C) | 0.77 (0.69–0.86) | |||
SUA + Model 1 vs Model 1 (model 1: HbA1c, SBP, DBP and LDL-C) | 0.04 (p=0.31) | 0.05±0.02 (p=0.01) | 38% (p=0.01) |
Relative IDI – calculated as the ratio of IDI over the discrimination slope of the model without the new variable (i.e. SUA).